Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $13.3636.

A number of brokerages have weighed in on CMPX. Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on shares of Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 target price on the stock. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “overweight” rating for the company. Finally, William Blair initiated coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating on the stock.

Compass Therapeutics Trading Down 2.2%

CMPX stock opened at $5.65 on Friday. The firm has a market cap of $1.00 billion, a P/E ratio of -12.56 and a beta of 1.46. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $6.88. The stock’s 50 day simple moving average is $5.86 and its 200 day simple moving average is $4.71.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CMPX. Suvretta Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares during the period. Vivo Capital LLC lifted its position in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after purchasing an additional 3,502,000 shares during the last quarter. BVF Inc. IL boosted its stake in Compass Therapeutics by 63.5% during the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after purchasing an additional 3,014,842 shares during the period. Balyasny Asset Management L.P. bought a new position in Compass Therapeutics in the 3rd quarter worth about $9,892,000. Finally, Braidwell LP acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $14,965,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.